# Actual Use Trial of Atorvastatin Calcium 10 mg

Study · id `cardio:ct-nct01964326` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01964326](<https://clinicaltrials.gov/study/NCT01964326>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01964326

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1311 participants.

## Technical summary

Registry record NCT01964326. Allocation not applicable; no masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2014-12 (actual). Results posted on 2016-01-27.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1311 participants (enrolled count; ClinicalTrials.gov record NCT01964326, source copy `cardio:ctgov-nct01964326-2021-02-21`, retrieved 2026-10-31)
- Start date: 2013-10 (registry gives no type) (ClinicalTrials.gov record NCT01964326, source copy `cardio:ctgov-nct01964326-2021-02-21`, retrieved 2026-10-31)
- Primary completion: 2014-12 (actual) (ClinicalTrials.gov record NCT01964326, source copy `cardio:ctgov-nct01964326-2021-02-21`, retrieved 2026-10-31)
- Completion: 2014-12 (actual) (ClinicalTrials.gov record NCT01964326, source copy `cardio:ctgov-nct01964326-2021-02-21`, retrieved 2026-10-31)
- Results first posted: 2016-01-27 (ClinicalTrials.gov record NCT01964326, source copy `cardio:ctgov-nct01964326-2021-02-21`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01964326, source copy `cardio:ctgov-nct01964326-2021-02-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01964326-2021-02-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: Actual Use Trial of Atorvastatin Calcium 10 mg
- Condition: Hypercholesterolemia
- Intervention (Drug): Atorvastatin calcium 10 mg
- Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (`cardio:org-pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc`)

## Provenance

Content hash: 303ab9ecbfe2ef8af87275b5c4c9beaffab1d83b009d7d67fb6f739748fac3b7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
